Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Rhea-AI Summary

Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. The company's Chief Scientific Officer and President, Steve Perrin, Ph.D., will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT).

Interested parties can register in advance for the webcast of the fireside chat. Following the live session, a replay will be made available on the Company's website under the Events section.

News Market Reaction – ELDN

+1.29%

+1.29% Session move

In the trading session that priced this news, ELDN gained 1.29%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT).

To register in advance for the fireside chat webcast, sign up here.

A webcast replay will be accessible following the live session on the Company’s website under Events.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When is Eledon Pharmaceuticals (ELDN) presenting at the Leerink Partners Conference 2025?

Eledon Pharmaceuticals (ELDN) will present on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT).

Who will represent ELDN at the Leerink Partners Global Healthcare Conference?

Steve Perrin, Ph.D., Chief Scientific Officer and President of Eledon Pharmaceuticals, will represent ELDN in a fireside chat.

How can investors access ELDN's presentation at the Leerink Conference?

Investors can register in advance for the webcast, and a replay will be available on Eledon's website under Events after the live session.

What type of presentation format will ELDN deliver at the Leerink Healthcare Conference?

ELDN will participate in a fireside chat format presentation at the conference.